Annals of the Rheumatic Diseases最新文献

{"title":"Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register.","authors":"Martin Schaefer, Alina Purschke, Vera Zietemann, Tatjana Rudi, Yvette Meissner, Adrian Richter, Sylvia Berger, Karin Rockwitz, Klaus Krüger, Karl Matthias Schneider, Anne C Regierer, Anja Strangfeld","doi":"10.1016/j.ard.2025.05.014","DOIUrl":"https://doi.org/10.1016/j.ard.2025.05.014","url":null,"abstract":"<p><strong>Objectives: </strong>To estimate the effects of Janus kinase inhibitors (JAKis) vs biologic disease-modifying antirheumatic drugs (bDMARDs) on the risk of incident malignancies (excluding nonmelanoma skin cancer) in patients and patient subgroups with rheumatoid arthritis.</p><p><strong>Methods: </strong>Episodes of disease-modifying antirheumatic drug (DMARD) treatment initiated between January 2017 and December 2020 and followed up to June 2024 in RABBIT, the German register for the long-term observation of therapy with biologics and targeted disease-modifying antirheumatic drugs in adult patients with rheumatoid arthritis, were analysed. Incidence rates (IRs) per 1000 patient-years with 95% CIs were calculated, and incident malignancy risk was estimated as hazard ratios (HRs) by inverse probability weighted adjusted Cox models.</p><p><strong>Results: </strong>Among 2285 JAKi and 4259 bDMARD treatment episodes, 88 and 135 malignancies occurred, respectively. JAKi treatments were dominated by baricitinib and tofacitinib, while most bDMARD treatments comprised tumour necrosis factor inhibitors. IRs were 11.6 (95% CI: 9.3, 14.3) in JAKi- and 8.9 (95% CI: 7.4, 10.5) in bDMARD-treated groups. The adjusted HR comparing JAKis with bDMARDs was 1.40 (95% CI: 1.09, 1.80). An increase in the malignancy risk for JAKi vs bDMARD treatment could only be observed in treatment episodes lasting longer than 16 months. The risk appeared higher in some subgroups of patients, including those who started treatment aged ≥60 years, patients with ≥3 prior conventional synthetic DMARD treatments, and patients with high disease activity.</p><p><strong>Conclusions: </strong>In this German observational cohort study, an overall small increase in malignancy risk for JAKi vs bDMARD treatment was observed, with more pronounced risks in some subgroups of patients. The observed risk should be carefully counterbalanced to the known malignancy risk associated with insufficient disease control.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144504743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of treatments in familial Mediterranean fever and its complications: a systematic review informing the EULAR/PReS recommendations for familial Mediterranean fever.","authors":"Erdal Sag, Teresa Otón, Loreto Carmona, Seza Ozen","doi":"10.1016/j.ard.2025.05.020","DOIUrl":"https://doi.org/10.1016/j.ard.2025.05.020","url":null,"abstract":"<p><strong>Objectives: </strong>To analyse the efficacy and safety of (1) the biological agents and tofacitinib in the treatment of familial Mediterranean fever (FMF); (2) the biological agents and tofacitinib in FMF patients with complications such as amyloidosis; and (3) the colchicine preparations and dosing strategies to serve as evidence supporting the updated European Alliance of Associations for Rheumatology (EULAR) recommendations.</p><p><strong>Methods: </strong>This was a systematic review (SR) of studies testing pharmacological treatments in FMF patients, including targets, dosing, tapering, and uses in AA amyloidosis. MEDLINE, Embase, and the Cochrane Library were searched, focusing on studies published after October 1, 2014. The Cochrane Risk of Bias tool and the Newcastle-Ottawa Scale were used to assess the risk of bias in the included randomised controlled trials (RCTs) and observational studies, respectively. Due to excess heterogeneity, results were synthesised qualitatively.</p><p><strong>Results: </strong>This SR included 42 studies for efficacy and safety (n = 1798 patients), 13 for tapering, and 31 for amyloidosis. Based on 6 RCTs of interleukin (IL)-1 blockers and observational studies, these biologicals seem to be effective in decreasing the number of attacks and acute-phase reactants and improving disease activity scores and patient-reported outcomes. They also seem relatively safe. An RCT showed the equivalence of once-daily vs twice-daily doses of colchicine. The evidence of AA amyloidosis was entirely observational but reassuring for a deadly complication.</p><p><strong>Conclusions: </strong>Biological agents, particularly IL-1 inhibitors, are effective and relatively safe options for FMF patients who do not respond to colchicine. These treatments may be promising alternatives for managing symptoms and preventing comorbidities in both paediatric and adult populations.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144493754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of canstatin on fibroblast-driven hypervascularisation in rheumatoid arthritis.","authors":"Corinna Heck, Birgit Zimmermann-Geller, Sophie Haun, Frederik Lötfering, Paula Welbrink, Daria Kürsammer, Klaus W Frommer, Mona Arnold-Gräf, Adelheid Korb-Pap, Anna Knothe, Nils Schulz, Stefan Simianer, Ingo Tarner, Walter Hermann, Christoph Biehl, Stefan Günther, Jürgen Steinmeyer, Katrin S Lips, Markus Rickert, Stefan Rehart, Ulf Müller-Ladner, Elena Neumann","doi":"10.1016/j.ard.2025.05.019","DOIUrl":"10.1016/j.ard.2025.05.019","url":null,"abstract":"<p><strong>Objectives: </strong>Hypervascularisation is a dominant feature of the inflamed synovium in rheumatoid arthritis (RA). As RA synovial fibroblasts (RASFs) are key cells of synovial pathophysiology and are located adjacent to the aberrant endothelial cells (ECs), we hypothesised that this interaction might be responsible for the pathological hypervascularisation.</p><p><strong>Methods: </strong>In the severe combined immunodeficiency (SCID) mouse model for RA, RASF-mediated helix-like vessel (HLV) formation was described and modulated by canstatin, an antiangiogenic collagen IV fragment that blocks the angiopoietin (ANGPT)/Tie2 pathway in EC. ANGPT2/CD31 and CXCL2 immunofluorescence on implants and human synovium was performed. RASF were stimulated with interleukin (IL)-1β once or repetitively and immunoassays, real-time polymerase chain reaction and RNA sequencing were performed. Two-dimensional (2D) tube formation and 3-dimensional spheroid-based assays using human umbilical vein ECs and fluorescent-stained RASF with/without canstatin, IL-11 and CXCL2 were evaluated.</p><p><strong>Results: </strong>In SCID mice, RASF-specific HLV formation started early and increased until day 30. The number of HLV was significantly reduced by canstatin. Compared to osteoarthritis synovium, ANGPT2 was significantly upregulated in RA vessels. Repetitive RASF stimulation significantly decreased IL-6, IL-11 and CXCL-2 compared to RASF stimulated once with IL-1β. When RASF was stimulated once, CXCL2 and IL-11 were significantly reduced along with 2D tube formation, while repetitive stimulation significantly attenuated hypervascularisation. RNAseq revealed underlying pathways leading to altered tube formation.</p><p><strong>Conclusions: </strong>We showed that RASF affect vascularisation in vitro and in vivo. The results support the idea that canstatin is able to alter the RASF pathological HLV formation. In the SCID mouse model, this was regulated on a molecular level mediated by ANGPT2 in a vascular endothelial growth factor A-independent manner, contributing significantly to one of the central aspects of RA pathophysiology.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144336269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The TFIID complex is a new autoantibody target in systemic sclerosis.","authors":"Jean-Baptiste Vulsteke, Birthe Michiels, Vanessa Smith, Yves Piette, Marie Vanthuyne, Carole Lacout, Antoine Brochard, Mohammed Tikly, Jonas De Leeuw, Doreen Dillaerts, Tom Dehaemers, Petra De Haes, Jan L Lenaerts, Daniel Blockmans, Neil McHugh, Sarah Tansley, Emeline Vinatier, Frédéric Houssiau, Carolien Bonroy, Ellen De Langhe, Xavier Bossuyt","doi":"10.1016/j.ard.2025.05.008","DOIUrl":"10.1016/j.ard.2025.05.008","url":null,"abstract":"","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144336270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) definition of clinical remission in gout.","authors":"Adwoa Dansoa Tabi-Amponsah, Sarah Stewart, Lisa K Stamp, William J Taylor, Robert Terkeltaub, Nicola Dalbeth","doi":"10.1016/j.ard.2025.05.017","DOIUrl":"10.1016/j.ard.2025.05.017","url":null,"abstract":"<p><strong>Objectives: </strong>In 2016, rheumatologists and gout researchers developed a preliminary definition for gout remission. A subsequent qualitative study involving people with gout identified redundancies in the preliminary definition, prompting the development of a simplified definition consisting of no gout flares over 12 months, absence of subcutaneous tophi and serum urate <0.36 mmol/L (6 mg/dL) over 12 months. Here, we describe the evaluation and validation of the simplified definition and endorsement of this definition as the Gout, Hyperuricemia, and Crystal-Associated Disease Network (G-CAN) definition of clinical remission in gout.</p><p><strong>Methods: </strong>After establishment of the simplified definition, this multiphase project involved consecutive steps: analysis of the definition across a range of gout clinical trial datasets and study populations, summary of evaluation and validation of this definition presented to G-CAN members, discussion of this definition by G-CAN members, voting and G-CAN Board endorsement.</p><p><strong>Results: </strong>The simplified definition exhibited face validity, construct validity, predictive validity, feasibility, responsiveness, and discrimination across a range of gout clinical trial datasets. It also captured both inflammatory disease activity and urate burden in gout and reflected the patient perspective on gout remission. It was suggested by G-CAN members to consider the definition as one for 'clinical gout remission' since there is no domain evaluating complete crystal dissolution. In voting, this definition was supported by 98% of G-CAN members, and the G-CAN Board endorsed the definition.</p><p><strong>Conclusions: </strong>The G-CAN definition is feasible and has high validity. We recommend that this definition is used when assessing clinical remission in gout.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correspondence to: 'Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database'.","authors":"Yan-Li Yang, Rong-Hong Guo, James Cheng-Chung Wei, Li-Yun Zhang","doi":"10.1016/j.ard.2025.04.026","DOIUrl":"10.1016/j.ard.2025.04.026","url":null,"abstract":"","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study Ann Rheum Dis. 2023;82:1404-1414.","authors":"Christopher T Ritchlin, Laura C Coates, Iain B McInnes, Philip J Mease, Joseph F Merola, Yoshiya Tanaka, Akihiko Asahina, Laure Gossec, Alice B Gottlieb, Richard B Warren, Barbara Ink, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Robert B M Landewé","doi":"10.1016/j.ard.2025.05.013","DOIUrl":"10.1016/j.ard.2025.05.013","url":null,"abstract":"","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic susceptibility to membranous lupus nephritis: a genome-wide association study.","authors":"Yang Liu, Ting Gan, Yuan-Yuan Qi, Meng Tan, Lin-Lin Xu, Yang Li, Jiong Liu, Shu Qu, Lizhong Wang, Gang Chen, Ji-Cheng Lv, Zhan-Zheng Zhao, Wenjian Bi, Peipei Zhang, Ming-Hui Zhao, Ying Tan, Swapan K Nath, Hong Zhang, Xu-Jie Zhou","doi":"10.1016/j.ard.2025.05.015","DOIUrl":"10.1016/j.ard.2025.05.015","url":null,"abstract":"","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autoreactive B cells in extremes of rheumatoid arthritis disease phenotypes.","authors":"Nienke J Blomberg, Hendy Kristyanto, Marloes Verstappen, Sam Neppelenbroek, Annette H M van der Helm-van Mil, René E M Toes, Hans Ulrich Scherer","doi":"10.1016/j.ard.2025.05.006","DOIUrl":"https://doi.org/10.1016/j.ard.2025.05.006","url":null,"abstract":"","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144324356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the limit of image resolution for human expert classification of vascular ultrasound images in giant cell arteritis and healthy subjects: the GCA-US-AI project.","authors":"Claus-Juergen Bauer, Stavros Chrysidis, Christian Dejaco, Matthew J Koster, Minna J Kohler, Sara Monti, Wolfgang A Schmidt, Chetan B Mukhtyar, Pantelis Karakostas, Marcin Milchert, Cristina Ponte, Christina Duftner, Eugenio de Miguel, Alojzija Hocevar, Annamaria Iagnocco, Lene Terslev, Uffe Møller Døhn, Berit Dalsgaard Nielsen, Aaron Juche, Luca Seitz, Kresten Krarup Keller, Rositsa Karalilova, Thomas Daikeler, Sarah Louise Mackie, Karina Torralba, Kornelis S M van der Geest, Dennis Boumans, Philipp Bosch, Alessandro Tomelleri, Markus Aschwanden, Tanaz A Kermani, Andreas Diamantopoulos, Ulrich Fredberg, Nevsun Inanc, Simon M Petzinna, Shadi Albarqouni, Charlotte Behning, Valentin Sebastian Schäfer","doi":"10.1016/j.ard.2025.05.010","DOIUrl":"https://doi.org/10.1016/j.ard.2025.05.010","url":null,"abstract":"<p><strong>Objectives: </strong>Prompt diagnosis of giant cell arteritis (GCA) with ultrasound is crucial for preventing severe ocular and other complications, yet expertise in ultrasound performance is scarce. The development of an artificial intelligence (AI)-based assistant that facilitates ultrasound image classification and helps to diagnose GCA early promises to close the existing gap. In the projection of the planned AI, this study investigates the minimum image resolution required for human experts to reliably classify ultrasound images of arteries commonly affected by GCA for the presence or absence of GCA.</p><p><strong>Methods: </strong>Thirty-one international experts in GCA ultrasonography participated in a web-based exercise. They were asked to classify 10 ultrasound images for each of 5 vascular segments as GCA, normal, or not able to classify. The following segments were assessed: (1) superficial common temporal artery, (2) its frontal and (3) parietal branches (all in transverse view), (4) axillary artery in transverse view, and 5) axillary artery in longitudinal view. Identical images were shown at different resolutions, namely 32 × 32, 64 × 64, 128 × 128, 224 × 224, and 512 × 512 pixels, thereby resulting in a total of 250 images to be classified by every study participant.</p><p><strong>Results: </strong>Classification performance improved with increasing resolution up to a threshold, plateauing at 224 × 224 pixels. At 224 × 224 pixels, the overall classification sensitivity was 0.767 (95% CI, 0.737-0.796), and specificity was 0.862 (95% CI, 0.831-0.888).</p><p><strong>Conclusions: </strong>A resolution of 224 × 224 pixels ensures reliable human expert classification and aligns with the input requirements of many common AI-based architectures. Thus, the results of this study substantially guide projected AI development.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}